Article Details
Retrieved on: 2020-10-22 20:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Therefore, NRG1 fusion can be treated with HER2/HER3 inhibitory <b>monoclonal</b> <b>antibodies</b> (mAbs), antibody-drug conjugates, EGFR tyrosine kinase ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here